A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
研究单位：[1]Janssen Research & Development, LLC[2]City of Hope Duarte,Duarte,California,United States,91010[3]City of Hope Orange County Lennar Foundation Cancer Center,Irvine,California,United States,92618[4]City of Hope Long Beach Elm,Long Beach,California,United States,90813[5]Orlando Health,Orlando,Florida,United States,32806[6]Astera Cancer Care,East Brunswick,New Jersey,United States,08816[7]NYU Langone Health Laura and Isaac Perlmutter Cancer Center,New York,New York,United States,10016[8]Providence Portland Medical Center,Portland,Oregon,United States,97213[9]Medical University of South Carolina,Charleston,South Carolina,United States,29425[10]Virginia Cancer Specialists,Fairfax,Virginia,United States,22031[11]IADT Instituto Argentino de Diagnostico y Tratamiento,Caba,Argentina,C1122[12]Centro Oncológico Korben,Ciudad Autonoma de Buenos Aires,Argentina,C1426AGE[13]Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica,Cordoba,Argentina,5000[14]Sanatorio Allende,Cordoba,Argentina,5000[15]Clínica Viedma,Viedma,Argentina,R8500ACE[16]Cancer Research SA,Adelaide,Australia,5000[17]Chris O'Brien Lifehouse,Camperdown,Australia,2050[18]Peter MacCallum Cancer Centre,Melbourne,Australia,3000[19]St John of God Hospital Murdoch,Murdoch,Australia,6150[20]Westmead Hospital,Westmead,Australia,2145[21]Fundacao Pio XII,Barretos,Brazil,14784-400[22]Cetus Oncologia,Belo Horizonte,Brazil,30110-017[23]Instituto Cionc de Ensino e Pesquisa S/S,Curitiba,Brazil,80810-050[24]Ynova Pesquisa Clinica,Florianopolis,Brazil,88020-210[25]Fundacao Sao Francisco Xavier HMC Unidade de Oncologia,Ipatinga,Brazil,35162 189[26]UPCO Unidade de Pesquisa Clinica em Oncologia,Pelotas,Brazil,96020 080[27]União Brasileira de Educação e Assistência-Hospital São Lucas da PUCRS,Porto Alegre,Brazil,90610-000[28]Impar Servicos Hospitalares S/A,Rio de Janeiro,Brazil,22061-080[29]Oncoclínicas Rio de Janeiro S.A.,Rio de Janeiro,Brazil,22250-905[30]Instituto D''Or de Pesquisa e Ensino (IDOR),Rio de Janeiro,Brazil,22281-100[31]Núcleo de Oncologia da Bahia,Salvador,Brazil,40170-110[32]CEPHO - Centro de Estudos e Pesquisa de Hematologia e Oncologia,Santo Andre,Brazil,09060-650[33]Impar Servicos Hospitalares SA - Hospital Nove de Julho,Sao Paulo,Brazil,01409-002[34]Núcleo de Pesquisa São Camilo,São Paulo,Brazil,04014-002[35]Onco Star SP Oncologia Ltda,São Paulo,Brazil,04543-000[36]Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein,São Paulo,Brazil,05652-900[37]The Ottawa Hospital Cancer Centre,Ottawa,Ontario,Canada,K1H 8L6[38]Princess Margaret Hospital,Toronto,Ontario,Canada,M5G 1Z5[39]Beijing Shijitan Hospital, Capital Medical University,Beijing,China,100038[40]Beijing Friendship Hospital, Capital Medical University,Beijing,China,100050[41]Peking University Third Hospital,Beijing,China,100191[42]Beijing Chest hospital, Capital medical university,Beijing,China,101149[43]Cancer Hospital Chinese Academy of Medical Sciences,Beijing,China,200240[44]Jilin cancer hospital,Changchun,China,130012[45]The First People''s Hospital Of Changzhou,Changzhou,China,213004[46]Sichuan Cancer Hospital,Chengdu,China,610041[47]West China Hospital, Sichuan University,Chengdu,China,610047[48]Chongqing University Cancer Hospital,Chongqing,China,400030[49]Southwest Hospital,ChongQing,China,400038[50]First Affiliated Hospital of Gannan Medical University,Ganzhou,China,341000[51]The First Affiliated Hospital, Sun Yat-sen University,Guang Zhou,China,510080[52]The Second Affiliated Hospital of Zhejiang University College of Medicine,Hangzhou,China,310009[53]Harbin medical university cancer hospital,Harbin,China,150081[54]Huizhou Municipal Central Hospital,Huizhou,China,516001[55]Huizhou First Hospital,Huizhou,China,516003[56]Liuzhou people''s Hospital,Liuzhou,China,545026[57]Fudan University Shanghai Cancer Center,Shanghai,China,200032[58]S
研究目的：
The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.
